Member Login
  1. Stocks
    2. /
  2. Smith & Nephew plc (LSE: SN.)
    3. /

LSE:SN. (Smith & Nephew plc)

About SN.

Medical devices group Smith & Nephew makes nearly half of its revenues through its orthopaedics division, which manufactures knee joints, braces and other supports. Established in 1931, the group now has interests all over the world.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Smith & Nephew plc (LSE: SN.) Latest News

    Investing Articles

    AstraZeneca plc vs Smith & Nephew plc: Which Is The Better Buy?

    | Peter Stephens

    Should you add AstraZeneca plc (LON: AZN) or Smith & Nephew plc (LON: SN) to your portfolio?

    Read more »

    Investing Articles

    Why Now Is A Great Opportunity To Take Profit On Takeover Target Smith & Nephew plc

    | Alessandro Pasetti

    Smith & Nephew plc (LON:SN) is not an opportunity at this price, argues this Fool.

    Read more »

    Investing Articles

    Why Smith & Nephew plc Is Attracting Interest From Stryker Corporation

    | Royston Wild

    Royston Wild explains why Smith & Nephew plc (LON: SN) could prove a shrewd purchase for Stryker Corporation (NYSE: SYK).

    Read more »

    Investing Articles

    Why Smith & Nephew plc’s Latest Failure Should Worry AstraZeneca plc And GlaxoSmithKline plc

    | Royston Wild

    Royston Wild explains how Smith and Nephew plc (LON: SN)'s latest testing woes underlines the precarious nature of drugs testing

    Read more »

    Investing Articles

    3 Neil Woodford Plays On Ageing Populations: AstraZeneca plc, Smith & Nephew plc And Capita PLC

    | G A Chester

    AstraZeneca plc (LON:AZN), Smith & Nephew plc (LON:SN) and Capita PLC (LON:CPI) could super-charge your portfolio.

    Read more »

    Investing Articles

    Are AstraZeneca plc & GlaxoSmithKline plc A Sound Investment Right Now?

    | Alessandro Pasetti

    AstraZeneca plc (LON:AZN) and GlaxoSmithKline plc (LON:GSK) could outperform companies operating in more troubled sectors, and for different reasons, argues…

    Read more »

    Investing Articles

    How Regulatory Wrath Has Hammered Investors In BP plc, HSBC Holdings plc And Smith & Nephew

    | Harvey Jones

    BP plc (LON: BP), HSBC Holdings plc (LON: HSBA) and Smith & Nephew plc (LON: SN) have all incurred costly…

    Read more »

    Investing Articles

    3 FTSE 100 Stocks Up On M&A Talk: Vodafone Group plc, Smith & Nephew plc And AstraZeneca plc

    | Alessandro Pasetti

    Vodafone Group plc (LON:VOD), Smith & Nephew plc (LON:SN) and AstraZeneca plc (LON:AZN) are under the spotlight.

    Read more »

    Investing Articles

    Neil Woodford’s Portfolio: Downside For BT Group plc, Centrica plc, Rolls-Royce Holdings plc, Smith & Nephew plc & G4S plc

    | Alessandro Pasetti

    Will Neil Woodford trim exposure to BT Group plc (LON:BT-A), Rolls-Royce Holdings plc (LON:RR), Centrica plc (LON:CNA), Smith & Nephew…

    Read more »

    Investing Articles

    Is AstraZeneca plc’s Latest Director Deal A Game-Changer?

    | Peter Stephens

    With AstraZeneca plc (LON:AZN)'s CEO buying shares this week, is it a significant event for investors?

    Read more »

    Investing Articles

    Is It Time To Cash In On Takeover Target Smith & Nephew plc?

    | Alessandro Pasetti

    Smith & Nephew (LON:SN) is still an appealing investment, argues this Fool.

    Read more »

    Company Comment

    Transcript: Should You Buy Shares In TSB?

    | Owain Bennallack

    Owain Bennallack debates the pros and cons of investing in the TSB spin-off with Nate Weisshaar and Mark Rogers.

    Read more »